Janssen-Hanmi Ends Ph2 Dual Agonist; Sanofi Efpeg Deal Restructured

Recently, there have been two seemingly interrelated announcements from Hanmi regarding the termination of their GLP-1/GCG dual agonist partnership with Janssen and a restructuring of the deal with Sanofi for efpeglenatide. Below, FENIX provides a summary of these news items and potential read-through.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.